Lowering cholesterol with medicine | Dr Thomas Dayspring and Dr Dan Soffer

Lipid-lowering therapies (LLTs) serve as essential tools for preventing atherosclerotic cardiovascular disease by reducing ApoB-containing lipoproteins. Statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors function through distinct pathways—such as inhibiting cholesterol synthesis or blocking intestinal absorption—but share the common goal of upregulating LDL receptor activity to clear atherogenic particles from circulation. While clinical guidelines provide a framework for treatment, proactive management often requires looking beyond 10-year risk assessments to initiate therapy earlier in life, particularly for those with significant lifetime exposure. Historical clinical trials, ranging from the 4S study to modern PCSK9 inhibitor research, demonstrate that lower LDL levels consistently correlate with reduced major adverse cardiovascular events. Effective prevention strategies increasingly rely on combination therapies and personalized approaches that balance potency, cost, and patient tolerance to achieve long-term cardiovascular health.